Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Sep 9.

Published in final edited form as: Acta Ophthalmol. 2021 Mar 19;100(1):e91–e99. doi: 10.1111/aos.14852

Table 3.

Orthoptic status at 1 year.

		Ranibizumab 0.12 mg (N = 9)	Ranibizumab 0.20 mg (N = 7)	Total (N = 16)
Fixation	Equal fixation OD/OS [N, infants (%)]	7 (78)	6 (86)	13 (81)
	Unequal fixation [N, infants (%)]	2 (22)	-	2 (13)
	No fixation [N, infants (%)]	-	1 (14)	1 (6)
Objection to occlusion	Equal objection [N, Infants (%)]	8 (100)	7 (100)	15 (100)
Objection to occlusion	Missing values [N, infants (%)]	1	-	1
Strabismus	No strabismus [N, infants (%)]	5 (56)	4 (57)	9 (56)
	Exotropia [N, infants (%)]	-	-	-
	Esotropia [N, infants (%)]	4 (44)	2 (29)	6 (38)
	Other [N, infants (%)]	-	1 (14)	1 (6)
Motility	Both eyes fix and follow without problems [N, infants (%)]	8 (89)	6 (86)	14 (88)
	Motility restricted in one eye [N, infants (%)]	-	-	-
	Motility restricted in both eyes [N, infants (%)]	1 (11)	-	1 (6)
	Not applicable due to lack of fixation [N, infants (%)]	-	1 (14)	1 (6)
Nystagmus^*	No nystagmus [N, infants (%)]	6 (67)	5 (71)	11 (69)
Nystagmus^*	Nystagmus in both eyes [N, infants (%)]	3 (33)	2 (29)	5 (31)

^*

See Table S3 for more information on nystagmus.